Improvement of Current Immunotherapies With Engineered Oncolytic Viruses That Target Cancer Stem Cells Publisher Pubmed



Soroush A¹ ; Shahhosseini R² ; Ghavamikia N³ ; Hjazi A⁴ ; Roudaki S⁵ ; Khalatbarilimaki M⁶ ; Mirbolouk M⁷ ; Pakmehr S⁸ ; Karimi P⁹ Show Affiliations
Source: Cell Biochemistry and Function Published:2024

Abstract

The heterogeneity of the solid tumor microenvironment (TME) impairs the therapeutic efficacy of standard therapies and also reduces the infiltration of antitumor immune cells, all of which lead to tumor progression and invasion. In addition, self-renewing cancer stem cells (CSCs) support tumor dormancy, drug resistance, and recurrence, all of which might pose challenges to the eradication of malignant tumor masses with current therapies. Natural forms of oncolytic viruses (OVs) or engineered OVs are known for their potential to directly target and kill tumor cells or indirectly eradicate tumor cells by involving antitumor immune responses, including enhancement of infiltrating antitumor immune cells, induction of immunogenic cell death, and reprogramming of cold TME to an immune-sensitive hot state. More importantly, OVs can target stemness factors that promote tumor progression, which subsequently enhances the efficacy of immunotherapies targeting solid tumors, particularly the CSC subpopulation. Herein, we describe the role of CSCs in tumor heterogeneity and resistance and then highlight the potential and remaining challenges of immunotherapies targeting CSCs. We then review the potential of OVs to improve tumor immunogenicity and target CSCs and finally summarize the challenges within the therapeutic application of OVs in preclinical and clinical trials. © 2024 John Wiley & Sons Ltd.